Fluorometric detection of protein-ligand engagement: The case of phosphodiesterase5

被引:5
作者
Di Rocco, Giulia [1 ]
Martinelli, Ilaria [1 ]
Pacifico, Salvatore [2 ]
Guerrini, Remo [2 ]
Cichero, Elena [3 ]
Fossa, Paola [3 ]
Franchini, Silvia [1 ,4 ]
Cardarelli, Silvia [4 ]
Giorgi, Mauro
Sola, Marco [1 ]
Ponterini, Glauco [1 ]
机构
[1] Univ Modena & Reggio Emilia, Dept Life Sci, Via Campi 103, I-41125 Modena, Italy
[2] Univ Ferrara, Dept Chem & Pharmaceut Sci, Via Fossato di Mortara 17-19, I-44100 Ferrara, Italy
[3] Univ Genoa, Sch Med & Pharmaceut Sci, Med Chem Sect, Dept Pharm, Viale Benedetto 15,3, I-16132 Genoa, Italy
[4] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Ple A Moro 5, I-00185 Rome, Italy
关键词
Phosphodiesterase; 5; Fluorometric ligand binding detection; Competitive displacement analysis; cGMPS-rhodamine; Forster resonance energy transfer (FRET); Affinity constant (K-d); CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; RESONANCE ENERGY-TRANSFER; CATALYTIC DOMAIN; BREAST-CANCER; EXPRESSION; CELLS; INHIBITORS; BINDING; MOLECULES; PDE5;
D O I
10.1016/j.jpba.2017.11.014
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Phosphodiesterases (PDEs) regulate the intracellular levels of cAMP and cGMP. The great clinical success of the PDE5 inhibitors, Sildenafil (Viagra), Vardenafil (Levitra) and Tadalafil (Cialis) has led to an increasing interest for this class of enzymes. Recent studies have shown a correlation between tumor growth and PDE5 overexpression, making PDE5-selective inhibitors promising candidates for cancer treatment. The search for such inhibitors rests today on radioactive assays. In this work, we exploit the conserved catalytic domain of the enzyme and propose a faster and safer method for detecting the binding of ligands and evaluate their affinities. The new approach takes advantage of Forster Resonance Energy Transfer (FRET) between, as the donor, a fluorescein-like diarsenical probe able to covalently bind a tetracysteine motif fused to the recombinant PDE5 catalytic domain and, as the acceptor, a rhodamine probe covalently bound to the pseudosubstrate cGMPS. The FRET efficiency decreases when a competitive ligand binds the PDE5 catalytic site and displaces the cGMPS-rhodamine conjugate. We have structurally investigated the PDES/cGMPS-rhodamine complex by molecular modelling and have used the FRET signal to quantitatively characterize its binding equilibrium. Competitive displacement experiments were carried out with tadalafil and cGMPS. An adaptation of the competitive-displacement equilibrium model yielded the affinities for PDE5 of the incoming ligands, nano- and micromolar, respectively. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:335 / 342
页数:8
相关论文
共 28 条
[1]   New biarsenical Ligands and tetracysteine motifs for protein labeling in vitro and in vivo: Synthesis and biological applications [J].
Adams, SR ;
Campbell, RE ;
Gross, LA ;
Martin, BR ;
Walkup, GK ;
Yao, Y ;
Llopis, J ;
Tsien, RY .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (21) :6063-6076
[2]   Interactions of AsCy3 with Cysteine-Rich Peptides [J].
Alexander, Seth C. ;
Schepartz, Alanna .
ORGANIC LETTERS, 2014, 16 (14) :3824-3827
[3]   Clinical and Molecular Genetics of the Phosphodiesterases (PDEs) [J].
Azevedo, Monalisa F. ;
Faucz, Fabio R. ;
Bimpaki, Eirini ;
Horvath, Anelia ;
Levy, Isaac ;
de Alexandre, Rodrigo B. ;
Ahmad, Faiyaz ;
Manganiello, Vincent ;
Stratakis, Constantine A. .
ENDOCRINE REVIEWS, 2014, 35 (02) :195-233
[4]   Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use [J].
Bender, Andrew T. ;
Beavo, Joseph A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :488-520
[5]   Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation [J].
Blount, MA ;
Beasley, A ;
Zoraghi, R ;
Sekhar, KR ;
Bessay, EP ;
Francis, SH ;
Corbin, JD .
MOLECULAR PHARMACOLOGY, 2004, 66 (01) :144-152
[6]   Structural basis for the activity of drugs that inhibit phosphodiesterases [J].
Card, GL ;
England, BP ;
Suzuki, Y ;
Fong, D ;
Powell, B ;
Lee, B ;
Luu, C ;
Tabrizizad, M ;
Gillette, S ;
Ibrahim, PN ;
Artis, DR ;
Bollag, G ;
Milburn, MV ;
Kim, SH ;
Schlessinger, J ;
Zhang, KYJ .
STRUCTURE, 2004, 12 (12) :2233-2247
[7]  
Corbin JD, 2002, INT J CLIN PRACT, V56, P453
[8]   Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5) [J].
Fink, TL ;
Francis, SH ;
Beasley, A ;
Grimes, KA ;
Corbin, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (49) :34613-34620
[9]   Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives [J].
Franchini, Silvia ;
Battisti, Umberto Maria ;
Prandi, Adolfo ;
Tait, Annalisa ;
Borsari, Chiara ;
Cichero, Elena ;
Fossa, Paola ;
Cilia, Antonio ;
Prezzavento, Orazio ;
Ronsisvalle, Simone ;
Arico, Giuseppina ;
Parenti, Carmela ;
Brasili, Livio .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 112 :1-19
[10]   Specific covalent labeling of recombinant protein molecules inside live cells [J].
Griffin, BA ;
Adams, SR ;
Tsien, RY .
SCIENCE, 1998, 281 (5374) :269-272